1. Developing Effective Drug Treatment For Adolescents: Results from the Cannabis Youth Treatment (CYT) Trials
Michael Dennis, Ph.D.
Chestnut Health Systems
Bloomington, IL
“Scientific Approaches to Improving Practice” Panel Presentation at the American Society of Addiction Medicine (ASAM) 2004 Annual Conference, Washington, DC, April 25, The opinions are those of the author do not reflect official positions of the government . Available on-line at

2. Acknowledgement This presentation is based on the work, input and contributions from several other people including: Nancy Angelovich, Tom Babor, Laura (Bunch) Brantley, Joseph A. Burleson, George Dent, Guy Diamond, James Fraser, Michael French, Rod Funk, Mark Godley, Susan H. Godley, Nancy Hamilton, James Herrell, David Hodgkins, Ronald Kadden, Yifrah Kaminer, Tracy L. Karvinen, Pamela Kelberg, Jodi (Johnson) Leckrone, Howard Liddle, Barbara McDougal, Kerry Anne McGeary, Robert Meyers, Suzie Panichelli-Mindel, Lora Passetti, Nancy Petry, M. Christopher Roebuck, Susan Sampl, Meleny Scudder, Christy Scott, Melissa Siekmann, Jane Smith, Zeena Tawfik, Frank Tims, Janet Titus, Jane Ungemack, Joan Unsicker, Chuck Webb, James West, Bill White, Michelle White, Caroline Hunter Williams, the other CYT staff, and the families who participated in this study. This presentation was supported by funds and data from the Center for Substance Abuse Treatment (CSAT’s) Persistent Effects of Treatment Study (PETS, Contract No ) and the Cannabis Youth Treatment (CYT) Cooperative Agreement (Grant Nos. TI11317, TI11320, TI11321, TI11323, and TI11324). The opinions are those of the author and steering committee and do not reflect official positions of the government .
We would like to start by acknowledging our other government, research and clinical colleagues, as well as the adolescents and their families who made this study possible.
As I think you will see in the course of this presentation,
we have worked together well to bridge the gap between
research and practice and have some great news to share with you today.

3. CYT Cannabis Youth Treatment Randomized Field Trial
One of the largest studies ever conducted of adolescent outpatient treatment, CYT involves a multi-center collaboration of
the Center for Substance Abuse Treatment (CSAT), (blue star), two of the country's largest providers of adolescent treatment, Operation Par in Florida and Chestnut Health System in Illinois, and two of our nationa's major medical centers, the Univ. of CT Health Center and the Children's Hosptial of Philadelphia (green boxes) as well as a coordinator center (red circles) led by Chestnut Health Systems with support from staff at UCHC and the University of Miami
Coordinating Center:
Chestnut Health Systems, Bloomington, IL,
and Chicago, IL
University of Miami, Miami, FL
University of Conn. Health Center, Farmington, CT
Sites:
Univ. of Conn. Health Center, Farmington, CT
Operation PAR, St. Petersburg, FL
Chestnut Health Systems, Madison County, IL
Children’s Hosp. of Philadelphia, Phil. ,PA
Sponsored by: Center for Substance Abuse Treatment (CSAT), Substance Abuse and Mental Health Services Administration (SAMHSA), U.S. Department of Health and Human Services

4. Objectives
Describe the development of manual-guided, cost-effective, outpatient treatment interventions for adolescent drug abusers.
Summarize methodological advances in assessment, retention, supervision, and follow-up
Summarize evidence on their cost, effectiveness, and cost-effectiveness
Examine the diffusion of these methodological and substantive advances to the field.
Let me start by briefly telling you about why this study was so important.
Marijuana use is starting at increasingly younger ages, with most starting in Junior high school and many starting even before that.
While there have been some recent reductions in use of 1 or 2 percent, the rates of adolescent use are literally twice as high as they were in 1992 for 8th graders.
Marijuana use is six times more likely to lead to problems related to dependence among adolescents as adults
Weekly adolescent marijuana use is associated with 3 to 40 times more emotional, behavioral, family, school and legal problems.
Marijauana is now the leading substance mentioned in adolescent emergency room admisisons and autopsies

5. The Adolescent Marijuana Problem (circa 1997-1998)
Use was starting at younger ages
Was at an historically high level among adolescents
Potency increased 3-fold from 1980 to 1997
Was three times more likely to lead to dependence among adolescents than adults
Was associated with many health, mental and behavioral problems
Was the leading substance mentioned in adolescent emergency room admissions and autopsies
Let me start by briefly telling you about why this study was so important.
Marijuana use is starting at increasingly younger ages, with most starting in Junior high school and many starting even before that.
While there have been some recent reductions in use of 1 or 2 percent, the rates of adolescent use are literally twice as high as they were in 1992 for 8th graders.
Marijuana use is six times more likely to lead to problems related to dependence among adolescents as adults
Weekly adolescent marijuana use is associated with 3 to 40 times more emotional, behavioral, family, school and legal problems.
Marijauana is now the leading substance mentioned in adolescent emergency room admisisons and autopsies

6. The State of Adolescent Treatment (circa 1997-1998)
Marijuana related admissions to adolescent substance abuse treatment increased by 115% from 1992 to 1998
Over 80% of adolescents entering treatment in 1998 had a marijuana problem
Over 80% were entering outpatient treatment
Over 75% received less than 90 days of treatment (median of 6 weeks)
Evaluations of existing adolescent outpatient treatment suggest that adult models or less than 90 days of outpatient treatment is rarely effective for reducing marijuana use.
No empirically evaluated treatment manuals were publicly available to help expand or enhance the system
From 1992 to 1997 the number of marijuana related admissions to adolescent substance abuse treatment doubled.
Of adolescents admitted to treatment in 1997, over 80% had a marijuana problem - more then even alcohol.
Over 80% of these adolescents are treated in outpatient settings.
Unfortunately evaluations of existing outpatient treatment practice have produced mixed results - with treatment outcomes ranging from decreasing use by 15% to increasing use by as much as 10%.
Moreover the handful of research studies that had been conducted were plagued by methodological problems such has having less then half the adolescents finish treatment and/or complete follow-up interviews.

7. Purpose of CYT
To learn more about the characteristics and needs of adolescent marijuana users presenting for outpatient treatment.
To adapt evidence-based, manual-guided therapies for use in 1.5 to 3 month adolescent outpatient treatment programs in medical centers or community based settings.
To field test the relative effectiveness, cost, cost-effectiveness, and benefit cost of five interventions targeted at marijuana use and associated problems in adolescents.
To provide validated models of these interventions to the treatment field in order to address the pressing demands for expanded and more effective services.
From here on from Dennis, Titus et al., under review

8. Design
Target Population: Adolescents with marijuana disorders who are appropriate for 1 to 3 months of outpatient treatment.
Inclusion Criteria: 12 to 18 year olds with symptoms of cannabis abuse or dependence, past 90 day use, and meeting ASAM criteria for outpatient treatment
Data Sources: self report, collateral reports, on-site and laboratory urine testing, therapist alliance and discharge reports, staff service logs, and cost analysis.
Random Assignment: to one of three treatments within site in two research arms and quarterly follow-up interview for 12 months
Long Term Follow-up: under a supplement from PETSA follow-up was extended to 30 months (42 for a subsample)

9. Two Trials or Study Arms
Incremental Arm
Alternative Arm
Randomly Assigns to:
Randomly Assigns to:
MET/CBT5
MET/CBT5
Motivational Enhancement Therapy/
Motivational Enhancement Therapy/
Cognitive Behavioral Therapy (5 weeks)
Cognitive Behavioral Therapy (5 weeks)
MET/CBT12
ACRA
Motivational Enhancement Therapy/
Adolescent Community
Cognitive Behavioral Therapy (12 weeks)
Reinforcement Approach(12 weeks)
FSN
MDFT
Family Support Network
Multidimensional Family Therapy
Plus MET/CBT12 (12 weeks)
(12 weeks)
Source: Dennis et al, 2002

10. Actual Treatment Received by Condition
ACRA and MDFT both rely on individual, family and case management instead of group
FSN adds multi family group, family home visits and more case management
And MDFT using more family therapy
MET/CBT12 adds 7 more sessions of group
With ACRA using more individual therapy
Source: Dennis, Godley et al, in press

11. Average Episode Cost ($US) of Treatment
| Economic Cost | Director Estimate-----|
Less than
average
for 6 weeks
Less than
average
for 12 weeks
$4,000
$1,776
$3,495
NTIES Est (6.7 weeks)
NTIES Est.(13.1 weeks)
$3,322
$3,500
$3,000
$2,500
Average Cost Per Client-Episode of Care
$1,984
$2,000
$1,559
$1,413
$1,500
$1,126
$1,197
$1,000
$500 $-
ACRA (12.8 weeks)
MET/CBT5 (6.8 weeks)
MET/CBT5 (6.5 weeks)
MET/CBT12 (13.4 weeks)
FSN (14.2 weeks w/family)
MDFT(13.2 weeks w/family)
Source: French et al., 2002, 2003

12. Implementation of Evaluation
Over 85% of eligible families agreed to participate
Quarterly follow-up of 94 to 98% of the adolescents from 3- to 12-months (88% all five interviews)
Long term follow-up completed on 90% at 30-months
Collateral interviews were obtained at intake, 3- and 6-months on over % of the adolescents interviewed
Urine test data were obtained at intake, 3, 6, 30 and 42 months % of the adolescents who were not incarcerated or interviewed by phone (85% or more of all adolescents).
Self report marijuana use largely in agreement with urine test at 30 months (13.8% false negative, kappa=.63)
5 Treatment manuals drafted, field tested, revised, send out for field review, and finalized (10-30,000 copies of each already printed and distributed)
Descriptive, outcome and economic analyses completed
cocaine (the adjusted kappa at 30 month for past month marijuana use is .63 withfalse neg. rate of 13.8%For cocaine, had 5% positive tests and 4% reporting past month use. Theadj. kappa is .67 with false neg. rate of 4.4%
Source: Dennis et al, 2002, in press

13. Adolescent Cannabis Users in CYT were
as or More Severe Than Those in TEDS*
Source: Tims et al, 2002

14. Demographic Characteristics
As shown here, the sample was predominately, male, caucasion or African American, 15 to 16 and from single parent households. With a sample size of 600 and follow-up rates over 95%, however, we are also able to break out large numbers of females and adolescents under the age of 15.
Source: Tims et al, 2002

15. Institutional Involvement
In addition to their families, most adolescents were also involved with several other systems - including school, work, the criminal justice system, and high cost controlled environments.
NOTE ONLY - controlled environment includes jail, hosptials, mental institutions, etc.
Source: Tims et al, 2002

16. Patterns of Substance Use
100%
73%
80%
71%
60%
40%
17%
20% 9%
As shown here, most of the adolescents were using tobacoo and marijuana regularly. It is important to note that marijuana use among these adolescents is quite heavy. 1 out of 5 were smoking the equivallent of 20 or more joints in a day - typically in the form of a 3 to 6 joint blunt.
Many are also regular alcohol users and/or spent significant time in a controlled environment prior to treatment.
Note only:
A blunt is a cigar that has been hollowed out and filled with marijuana. 0%
Weekly
Weekly
Weekly Alcohol
Significant Time
Tobacco Use
Cannabis Use
Use
in Controlled
Environment
Source: Tims et al, 2002

17. Multiple Problems are the NORM
Self-Reported in Past Year
Joan note-again, to what do the asteriks on the bottom row refer - is there an explanatory note missing?
Let me conclude this description of the population by noting that most of our adolescents actually had multiple problems. Moreover, those with dependence were significantly more likely to report having these problems in the past year.
NOTE ONLY:
Measured with GAIN.
Source: Dennis et al, under review

18. Co-occurring Problems are Higher for those Self-Reporting Past Year Dependence
Let me conclude this description of the population by noting that most of our adolescents actually had multiple problems. Moreover, those with dependence were significantly more likely to report having these problems in the past year.
NOTE ONLY:
Measured with GAIN.
Source: Tims et al., * p<.05

19. CYT Increased Days Abstinent and Percent in Recovery (no use or problems while in community)
Let me conclude this description of the population by noting that most of our adolescents actually had multiple problems. Moreover, those with dependence were significantly more likely to report having these problems in the past year.
NOTE ONLY:
Measured with GAIN.
Source: Dennis et al., in press

20. Similarity of Clinical Outcomes by Conditions
Let me conclude this description of the population by noting that most of our adolescents actually had multiple problems. Moreover, those with dependence were significantly more likely to report having these problems in the past year.
NOTE ONLY:
Measured with GAIN.
Source: Dennis et al., in press.

21. Moderate to large differences in Cost-Effectiveness by Condition
ACRA did better than MET/CBT5, and both did better than MDFT
MET/CBT5 and 12 did better than FSN
Let me conclude this description of the population by noting that most of our adolescents actually had multiple problems. Moreover, those with dependence were significantly more likely to report having these problems in the past year.
NOTE ONLY:
Measured with GAIN.
Source: Dennis et al., in press

22. Evaluating the Long Term Effects of Treatment
Treatment Outcome
Difference between intake and average of all short term
follow-ups (3-12)
Long Term Stability
Difference between average of short term follow-ups (3-12) and long term follow-up (30)
Month
Z-Score
Joan note-left-hand key should read "Days of cannabis Use" This is ALSO true for #47
Short Term Outcome Stability
Difference between average of early (3-6) and latter (9-12) follow-up interviews
Source: Dennis et al, under review, forthcoming

23. Cumulative Recovery Pattern at 30 months: (The Majority Vacillate in and out of Recovery)
Source: Dennis et al, forthcoming

24. Cost Per Person in Recovery at 12 and 30
Months After Intake by CYT Condition
Stability of MET/CBT-5 findings mixed at 30 months
Trial 1 (n=299)
Trial 2 (n=297)
Cost Per Person in
Recovery (CPPR)
MET/CBT-5, -12 and ACRA more cost effective at
12 months
$30,000
CPPR at 30 months**
$6,437
$10,405
$24,725
$27,109
$8,257
$14,222
$25,000
$20,000
$15,000
$10,000
$5,000 $0
MET/ CBT5
MET/ CBT12
FSNM
MET/ CBT5
ACRA
MDFT
* Cost Per Person in Recovery (CPPR) at month 12 statistically significant by condition (p<.05) after controlling for site and recovery status in the month before intake; CPPR Effect size f=1.42 in Trial 1 and f=1.77 in Trial 2.
** Cost Per Person in Recovery (CPPR) at month 30 statistically significant by condition (p<.05) after controlling for site and recovery status in the month before intake; CPPR Effect size f=0.76 in Trial 1 and f=0.94 in Trial 2.
CPPR at 12 months*
$3,958
$7,377
$15,116
$6,611
$4,460
$11,775
Integrated family therapy (MDFT) was more cost effective than adding it on top of treatment (FSN) at 30 months
* P<.0001, Cohen’s f= 1.42 and 1.77 at 12 months
** P<.0001, Cohen’s f= 0.76 and 0.94 at 30 months
Source: Dennis et al., in press; forthcoming

25. Average Cost to Society Varied More by Site than Condition
UCHC, Farmington, CT (-24%, -44%)
PAR, St. Petersburg, FL (-22%, -49%)
CHS, Madison Co., IL (-8%, -51%)
CHOP, Philadelphia, PA (+18%, -34%)
$6,000
$5,000
$4,000
$3,000
$2,000
$1,000 $0 3 6 9 12 15 18 21 24 27 30
Months from Intake
Source: French et al, 2003; forthcoming

26. How does CYT compare with Regular OP/IOP: Frequency of Substance Use

27. How does CYT compare with Regular OP/IOP: Substance Abuse/Dependence Problems

28. Dissemination and Impact
Papers published on design, validation, characteristics, matching, clinical contrast, treatment manuals, therapist reactions, 6 month outcomes, cost, benefit cost
Papers with main clinical and cost-effectiveness findings at 12 months in press and 30 month findings being submitted this year.
Interventions being replicated as part of over four dozen studies currently or about to go into the field
20 to 30,000 copies of each of the 5 manuals distributed to policy makers, providers, individual clinicians and training programs (via NCADI or )
The Global Appraisal of Individual Needs (GAIN) assessment has been used in over 70 subsequent adolescent treatment studies and combined into one large data base that will be used to support case mix adjustments, benchmarking and meta analysis
Supervision, Retention, and Follow-up models also being replicated in these adolescent treatment studies

29. CYT was part of a Renascence of Adolescent Treatment Research/Practice
From 1998 to 2002 the number of adolescent treatment studies doubled and has doubled again in the past 2 years – with over 100 currently in the field
Source: Dennis &, White (2003) at

30. CSAT’s Adolescent Treatment Programs
Currently Using the GAIN or CYT Txs
CSAT Grantees
Other Collaborators
Cannabis Youth Treatment (CYT)
Adolescent Treatment Model (ATM)
RWJF Reclaiming Futures Program
Strengthening Communities for Youth (SCY)
RWJF Other RWJF Grantees
Adolescent Residential Treatment (ART)
NIAAA/NIDA Other Grantees
Effective Adolescent Treatment (EAT)
Other CSAT Grantees

31. Conclusions
The CYT interventions provide replicable models of effective brief (1.5 to 3 month) treatments that can be used to help the field maintain quality while expanding capacity.
While a good start, the CYT interventions were still not an adequate dose of treatment for the majority of adolescents.
The majority of adolescents continued to vacillate in and out of recovery after discharge from CYT.
More work needs to be done on providing a continuum of care, longer term engagement and on going recovery management.
Adolescent treatment can be cost effective and cost beneficial to society
CYT also helped to spur a new wave of methodological improvements related to assessment, supervision, retention, and follow-up that benefit researchers, evaluators, and program planners

32. Contact Information
Michael L. Dennis, Ph.D., CYT Coordinating Center PI
Lighthouse Institute, Chestnut Health Systems
720 West Chestnut, Bloomington, IL 61701
Phone: (309) , Fax: (309)
Manuals and Additional Information are Available at:
CYT: or
PETSA:
(then select PETS from program resources)
APSS:
(copies of CYT and over a dozen other adolescent treatment
manuals and information on the Society for Adolescent
Substance Abuse Treatment Effectiveness (SASATE)

33. CYT Related References
Babor, T. F., Webb, C. P. M., Burleson, J. A., & Kaminer, Y. (2002). Subtypes for classifying adolescents with marijuana use disorders Construct validity and clinical implications. Addiction, 97(Suppl. 1),
Buchan, B. J., Dennis, M. L., Tims, F. M., & Diamond, G. S. (2002). Cannabis use Consistency and validity of self report, on-site urine testing, and laboratory testing. Addiction, 97(Suppl. 1),
Dennis, M. L., Babor, T., Roebuck, M. C., & Donaldson, J. (2002). Changing the focus The case for recognizing and treating marijuana use disorders. Addiction, 97 (Suppl. 1), S4-S15.
Dennis, M.L., Dawud-Noursi, S., Muck, R., & McDermeit, M. (2003). The need for developing and evaluating adolescent treatment models. In S.J. Stevens & A.R. Morral (Eds.), Adolescent substance abuse treatment in the United States: Exemplary Models from a National Evaluation Study (pp. 3-34). Binghamton, NY: Haworth Press and 1998 NHSDA.
Dennis, M. L., Godley, S. H., Diamond, G., Tims, F. M., Babor, T., Donaldson, J., Liddle, H., Titus, J. C., Kaminer, Y., Webb, C., Hamilton, N., & Funk, R. (in press). The Cannabis Youth Treatment (CYT) Study: Main Findings from Two Randomized Trials. Journal of Substance Abuse Treatment.
Dennis, M. L., Godley, S. and Titus, J. (1999). Co-occurring psychiatric problems among adolescents: Variations by treatment, level of care and gender. TIE Communiqué (pp. 5-8 and 16). Rockville, MD: Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment.
Dennis, M. L. and McGeary, K. A. (1999). Adolescent alcohol and marijuana treatment: Kids need it now. TIE Communiqué (pp ). Rockville, MD: Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment.
Dennis, M. L., Titus, J. C., Diamond, G., Donaldson, J., Godley, S. H., Tims, F., Webb, C., Kaminer, Y., Babor, T., Roebuck, M. C., Godley, M. D., Hamilton, N., Liddle, H., Scott, C. K., & CYT Steering Committee. (2002). The Cannabis Youth Treatment (CYT) experiment Rationale, study design, and analysis plans. Addiction, 97 (Suppl. 1), S16-S34.
Dennis, M.L., & White, M.K. (2003). The effectiveness of adolescent substance abuse treatment: a brief summary of studies through 2001, (prepared for Drug Strategies adolescent treatment handbook). Bloomington, IL: Chestnut Health Systems. [On line] Available at
Dennis, M.L., White,M.A., Titus, J.C. & Godley, M.D. (in press). The effectiveness of adolescent substance abuse treatment: a brief summary of studies through (prepared for Drug Strategies adolescent treatment handbook). Bloomington, IL: Chestnut Health Systems.
Diamond, G., Leckrone, J., & Dennis, M. L. (In press). The Cannabis Youth Treatment study Clinical and empirical developments. In R. Roffman, & R. Stephens, (Eds.) Cannabis dependence Its nature, consequences, and treatment . Cambridge, UK Cambridge University Press.
Diamond, G., Panichelli-Mindel, S. M., Shera, D., Dennis, M. L., Tims, F., & Ungemack, J. (in press). Psychiatric syndromes in adolescents seeking outpatient treatment for marijuana with abuse and dependency in outpatient treatment. Journal of Child and Adolescent Substance Abuse.

34. CYT Related References - continued
Godley, M.D., Kahn, J.H., Dennis, M.L., Godley, S.H., & Funk, R.R. (in press). The stability and impact of environmental factors on substance use and problems after adolescent outpatient treatment. Psychology of Addictive Behavior.
Godley, S. H., White, W. L., Diamond, G., Passetti, L., & Titus, J. (2001). Therapists' reactions to manual-guided therapies for the treatment of adolescent marijuana users. Clinical Psychology Science and Practice, 8(4),
Godley, S. H., Meyers, R. J., Smith, J. E., Godley, M. D., Titus, J. M., Karvinen, T., Dent, G., Passetti, L., & Kelberg, P. (2001). The Adolescent Community Reinforcement Approach (ACRA) for adolescent cannabis users (Cannabis Youth Treatment (CYT) Manual Series, No. Volume 4). Rockville, MD Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration.
Hamilton, N., Brantley, L., Tims, F., Angelovich, N., & McDougall, B. (2001). Family Support Network (FSN) for adolescent cannabis users (Cannabis Youth Treatment (CYT) Manual Series, No. Volume 3). Rockville, MD Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration.
Jensen, K. A. (2001). The effects of adolescent peer-based intervention Contextual influence of peers during cannabis treatment. University of South Florida.
Liddle, H. A. (2002). Multidimensional Family Therapy (MDFT) for adolescent cannabis users (Cannabis Youth Treatment (CYT) Manual Series, No. Volume 5). Rockville, MD Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration.
Petry, N. M., & Tawfik, Z. (2001). A comparison of problem gambling and non-problem gambling youth seeking treatment for marijuana abuse. Journal of the American Academy of Child and Adolescent Psychiatry, 40(11),
Roebuck, M. C., French, M. T., & Dennis, M. L. (2004). Adolescent marijuana use and school attendance. Economics of Education Review, 23(2),
Sampl, S., & Kadden, R. (2001). Motivational Enhancement Therapy and Cognitive Behavioral Therapy for Adolescent Cannabis Users 5 Sessions (Cannabis Youth Treatment (CYT) Manual Series, No. Volume 1). Rockville, MD Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration.
Tims, F. M., Dennis, M. L., Hamilton, N., Buchan, B. J., Diamond, G. S., Funk, R., & Brantley, L. B. (2002). Characteristics and problems of 600 adolescent cannabis abusers in outpatient treatment . Addiction, 97,
Titus, J. C., & Dennis, M. L. (in press). Cannabis Youth Treatment (CYT) Overview and summary of preliminary findings. H. A. Liddle, & C. L. Rowe (Eds.), Treating adolescent substance abuse State of the science . Cambridge, UK Cambridge University Press.
Titus, J. C., Dennis, M. L., White, W. L., Scott, C. K., & Funk, R. R. (2003). Gender differences in victimization severity and outcomes among adolescents treated for substance abuse. Journal of Child Maltreatment, 8,
Webb, C., Scudder, M., Kaminer, Y., Kadden, R., & Tawfik, Z. (2002). The MET/CBT 5 Supplement 7 Sessions of Cognitive Behavioral Therapy (CBT 7) for adolescent cannabis users (Cannabis Youth Treatment (CYT) Manual Series, No. Volume 2). Rockville, MD Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration.